Analyst Consensus ?
ConsensusBuy12 ratings
Bullish975.0%
Neutral216.7%
Bearish18.3%
Solventum Corporation · SOLV · FY2025 Q2 · Calendar Q3 2025
Solventum raises FY2025 outlook as separation and product launches progress
The current analysis supports a constructive but qualified view of Solventum's operating trajectory: management reported 2.8% organic sales growth, raised FY2025 guidance, and highlighted product launches and separation milestones. The evidence is about operating progress, not a forecast of the stock's one-year return.
Reported After market closeNYSEHealthcare
$14.87B market cap
100quality score
Earnings scorecard
Reported versus consensus
Reported EPS
$1.69
Consensus $1.45
EPS surprise
+16.6%
Reported versus consensus
Reported revenue
$2.16B
Consensus $2.12B
Revenue surprise
+2.0%
Reported versus consensus
Market reaction
event-close to next-session close
Stock move
+2.0%
Event window
SPY move
+0.8%
Same window
Abnormal move
+1.2%
Stock minus SPY
Volume
2.8×
Versus trailing sessions
Subsequent drift
+1.6%
Up to 20 sessions
SOLVSPY benchmark
Ask FN2 about SOLV FY2025 Q2
Transcript, numbers and history already loaded
Why did SOLV rise 2.0% after beating EPS estimates in FY2025 Q2?What changed in SOLV's guidance and outlook in FY2025 Q2?Give me the bull and bear case for SOLV after FY2025 Q2 earnings.
Free account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
Relative to the prior-quarter analysis, management reported stronger Q2 organic sales growth and raised both organic sales growth and EPS guidance. The current analysis also highlights a completed major ERP cutover in Europe, lower estimated tariff impact of $60-$80 million, the Ensemble partnership, and progress toward the Purification & Filtration transaction while retaining the drinking water business.
Guidance delta
Management raised FY2025 organic sales growth guidance to 2%-3% and EPS guidance to $5.80-$5.95.
Key takeaways
- Q2 organic sales growth was 2.8%, with management citing performance across MedSurg, Dental Solutions, and Health Information Systems.
- Management raised organic sales growth and EPS guidance for FY2025.
- The separation from 3M is progressing, including a major ERP cutover in Europe and distribution-center transitions.
- The Purification & Filtration transaction with Thermo remains on track for year-end close, while the drinking water business is being retained.
- A partnership with Ensemble is intended to support autonomous coding capabilities in revenue cycle management.
Management priorities
- Launch additional negative-pressure wound-therapy products and expand Peel and Place in Europe.
- Continue dental product launches including Clinpro Clear, Filtek Easy Match, and Clarity Precision Grip Attachments.
- Complete scheduled ERP cutovers and the separation from 3M.
- Pursue disciplined tuck-in M&A to accelerate growth.
- Expand 360 Encompass installations in Australia and the Middle East.
Follow SOLV with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Estimate
Beat
Miss
Match
Analyst 52W Price Targets
$87.29Current
$43Low
$85.1Average
$113High
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Oct 10, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| BTIG | Buy | Buy | Maintain | Sep 14, 2026 |
| Wedbush | Outperform | Outperform | Maintain | Aug 6, 2026 |
| UBS | Buy | Buy | Maintain | Aug 6, 2026 |
| Stifel | Buy | Buy | Maintain | Aug 6, 2026 |
| Piper Sandler | Overweight | Overweight | Maintain | Aug 6, 2026 |
| Keybanc | Overweight | Overweight | Maintain | Aug 6, 2026 |
| Wells Fargo | Equal Weight | Equal Weight | Maintain | May 6, 2026 |
| Mizuho | Outperform | Neutral | Upgrade | Jan 20, 2026 |
| Morgan Stanley | Overweight | Equal Weight | Upgrade | Jul 15, 2025 |
| Argus Research | Buy | Hold | Upgrade | Jul 1, 2025 |
| Goldman Sachs | Sell | Sell | Maintain | Mar 3, 2025 |
| B of A Securities | Neutral | Neutral | Maintain | Feb 26, 2025 |
Named analyst price targets
Upside is calculated against the persisted current price $87.29. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Stifel Nicolaus | Analyst unavailable | $100 | $84.82 | +14.6% | Aug 6, 2026 |
| UBS | Patrick Wood | $101 | $87.47 | +15.7% | Aug 6, 2026 |
| Mizuho Securities | Analyst unavailable | $113 | $87.47 | +29.5% | Aug 6, 2026 |
| KeyBanc | Analyst unavailable | $102 | $87.47 | +16.9% | Aug 6, 2026 |
| BTIG | Ryan Zimmerman | $95 | $87.47 | +8.8% | Aug 6, 2026 |
| UBS | Analyst unavailable | $95 | $80.47 | +8.8% | Jul 28, 2026 |
| BTIG | Analyst unavailable | $91 | $76.7 | +4.3% | Jul 13, 2026 |
| BMO Capital | Analyst unavailable | $81 | $75.18 | -7.2% | Jul 8, 2026 |
| Jefferies | Analyst unavailable | $43 | $74.95 | -50.7% | Jun 1, 2026 |
| Wedbush | Michael Piccolo | $94 | $74.42 | +7.7% | May 15, 2026 |
| UBS | Kevin Caliendo | $78 | $71.36 | -10.6% | May 6, 2026 |
| Stifel Nicolaus | Analyst unavailable | $90 | $69.04 | +3.1% | May 6, 2026 |
| KeyBanc | Brett Fishbin | $93 | $69.04 | +6.5% | May 6, 2026 |
| KeyBanc | Brett Fishbin | $92 | $68.52 | +5.4% | Apr 27, 2026 |
| Piper Sandler | Analyst unavailable | $92 | $68.88 | +5.4% | Apr 17, 2026 |
| KeyBanc | Brett Fishbin | $97 | $78.91 | +11.1% | Jan 26, 2026 |
| Mizuho Securities | Analyst unavailable | $100 | $79.48 | +14.6% | Jan 20, 2026 |
| Stifel Nicolaus | Analyst unavailable | $105 | $83.16 | +20.3% | Jan 7, 2026 |
| BTIG | Ryan Zimmerman | $100 | $85.56 | +14.6% | Dec 2, 2025 |
| UBS | Kevin Caliendo | $77 | $73 | -11.8% | Oct 1, 2025 |
| Morgan Stanley | Patrick Wood | $103 | $73.68 | +18.0% | Jul 15, 2025 |
| Mizuho Securities | Analyst unavailable | $82 | $80.16 | -6.1% | Mar 3, 2025 |
| Wells Fargo | Analyst unavailable | $75 | $79.75 | -14.1% | Feb 28, 2025 |
| Mizuho Securities | Steven Valiquette | $70 | $72.28 | -19.8% | Dec 3, 2024 |
| Stifel Nicolaus | Rick Wise | $82 | $66.29 | -6.1% | Oct 7, 2024 |
| Piper Sandler | Jason Bednar | $71 | $67.74 | -18.7% | Oct 7, 2024 |
| Morgan Stanley | Patrick Wood | $55 | $49 | -37.0% | Jul 15, 2024 |
| Goldman Sachs | David Roman | $54 | $59.72 | -38.1% | May 30, 2024 |
| Morgan Stanley | Patrick Wood | $70 | $65.52 | -19.8% | Apr 9, 2024 |
| Wells Fargo | Vik Chopra | $69 | $70.06 | -21.0% | Apr 8, 2024 |
Track every rating change on SOLV the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationSolventum Corporation, established in 2023 and headquartered in Saint Paul, Minnesota, operates as a healthcare entity dedicated to pioneering, producing, and commercializing diverse solutions that address critical needs for both customers and patients. The company's business activities are organized into four principal segments. The Medsurg division furnishes various products and services, including sophisticated wound care items, intravenous (I.V.) site management tools, sterilization assurance systems, temperature regulation devices, surgical instruments, stethoscopes, and medical electrodes.…
Historical context
All SOLV earningsHealthcare peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| COO The Cooper Companies, Inc. | FY2026 Q3 · Calendar Q3 2026 | +2.7% | -14.7% | CooperCompanies beats expectations as inventory reduction weighs on vision revenue |
| MDT Medtronic plc | FY2027 Q1 · Calendar Q3 2026 | +4.3% | +1.5% | Medtronic raises FY27 outlook as growth broadens across platforms |
Latest beats and misses
Who reports nextBeat on EPS
Get the SOLV recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
- FN2 earnings calendar · 2026-07-26T00:37:12.209961+00:00
- Polygon adjusted daily market bars · 2026-10-09T22:40:44.387844+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-10-09T22:40:44.385017+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-10-09. For educational purposes only; not investment advice.